This review discusses the evidence in support of the use of infiximab (REMICADE®), a chimeric monoclonal antibody against tumour necrosis factor (TNF)-alpha for the treatment of infammatory bowel disease (IBD). Since its introduction a decade ago infiximab (IFX) has revolutionised the management of complicated IBD, provided patient choice, enhanced quality of life and raised the bar for expected therapeutic outcomes from disease control to deep remission with complete mucosal healing and symptom resolution.
Download PDF